Access

You are not currently logged in.

Access your personal account or get JSTOR access through your library or other institution:

login

Log in to your personal account or through your institution.

A Response to Strategy #2: Streamlining the Regulatory Process

W. Paul Glezen
Clinical Infectious Diseases
Vol. 42, Supplement 3. Strengthening the Supply of Routinely Administered Vaccines in the United States: Presentations at Workshops Convened by the National Vaccine Advisory Committee, Department of Health and Human Services, February 2002 and January 2005 (Mar. 1, 2006), pp. S141-S144
Published by: Oxford University Press
Stable URL: http://www.jstor.org/stable/4463699
Page Count: 4
  • Download ($42.00)
  • Subscribe ($19.50)
  • Cite this Item
A Response to Strategy #2: Streamlining the Regulatory Process
Preview not available

Abstract

Regulatory burden has contributed to the decline in the production of vaccines in the United States. Production of influenza virus vaccine is perilously limited at a critical period when vulnerable populations are increasing and the threat of a pandemic is looming. Regulatory bodies must work with manufacturers to facilitate implementation of new production practices, to ensure steady expansion of the supply of safe and effective vaccines.

Page Thumbnails

  • Thumbnail: Page 
S141
    S141
  • Thumbnail: Page 
S142
    S142
  • Thumbnail: Page 
S143
    S143
  • Thumbnail: Page 
S144
    S144